FinscoFinsco

Aktis Oncology (US.AKTS)

Capital Allocation Audit · Period: 2022 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.AKTS · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion107.6%→
ROE-3.6%→
Cash Conversion-→
D/E Ratio0.02→
Gross Margin0.0%↓
US.AKTS (Aktis Oncology) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   107.6%    →
ROE               -3.6%    →
Cash Conversion       -    →
D/E Ratio          0.02    →
Gross Margin       0.0%    ↓
Key Metrics
US.AKTS (Aktis Oncology) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 107.6% →
ROE -3.6% →
Cash Conversion - →
D/E Ratio 0.02 →
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies